SEC Comment Letter for Wave Life Sciences, (WVE) — Dec 6, 2019
Wave Life Sciences, Inc.
Date: Dec. 6, 2019 · CIK: 0001631574 · Accession: 0000000000-19-016177
AI Filing Summary & Sentiment
File numbers found in text: 001-37627
Letter
December 6, 2019 Keith Regnante Chief Financial Officer Wave Life Sciences Ltd. 7 Straits View #12-00 Marina One East Tower Singapore 018936 Re:Wave Life Sciences Ltd. Form 10-K for fiscal year ended December 31, 2018 Filed March 1, 2019 File No. 001-37627 Dear Mr. Regnante: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
December 6, 2019
Keith Regnante
Chief Financial Officer
Wave Life Sciences Ltd.
7 Straits View #12-00
Marina One East Tower
Singapore 018936
Re:Wave Life Sciences Ltd.
Form 10-K for fiscal year ended December 31, 2018
Filed March 1, 2019
File No. 001-37627
Dear Mr. Regnante:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences